See more : Core Assets Corp. (CCOOF) Income Statement Analysis – Financial Results
Complete financial analysis of Summit Therapeutics Inc. (SMMT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Summit Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Clovis Oncology, Inc. (CLVS) Income Statement Analysis – Financial Results
- China Kangda Food Company Limited (0834.HK) Income Statement Analysis – Financial Results
- AegirBio AB (publ) (AEGIR.ST) Income Statement Analysis – Financial Results
- AXMIN Inc. (AXMIF) Income Statement Analysis – Financial Results
- Groupe Minoteries SA (0QMM.L) Income Statement Analysis – Financial Results
Summit Therapeutics Inc. (SMMT)
About Summit Therapeutics Inc.
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 704.30K | 1.81M | 860.00K | 632.02K | 56.41M | 35.98M | 2.88M | 0.00 | 2.27M | 2.27M | 2.87M | 2.77M | 1.21M | 301.95K | 266.64K | 6.03M | 2.03M | 947.89K | 212.76K | 1.82K |
| Cost of Revenue | 2.05M | 2.51M | 0.00 | 0.00 | 155.40K | 24.92K | 97.67K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01M | 0.00 | 0.00 | 5.77K | 2.51M | 596.30K | 415.93K | 169.46K | 1.82K |
| Gross Profit | -2.05M | -1.81M | 1.81M | 860.00K | 476.62K | 56.39M | 35.88M | 2.88M | 0.00 | 2.27M | 2.27M | 2.87M | 1.77M | 1.21M | 301.95K | 260.87K | 3.51M | 1.43M | 531.96K | 43.31K | 0.00 |
| Gross Profit Ratio | 0.00% | -256.95% | 100.00% | 100.00% | 75.41% | 99.96% | 99.73% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 63.68% | 100.00% | 100.00% | 97.84% | 58.28% | 70.60% | 56.12% | 20.35% | 0.00% |
| Research & Development | 59.47M | 52.00M | 85.35M | 53.27M | 32.71M | 51.38M | 41.01M | 23.69M | 23.94M | 15.64M | 10.83M | 5.72M | 4.78M | 3.66M | 3.68M | 7.38M | 15.34M | 5.79M | 1.83M | 504.60K | 0.00 |
| General & Administrative | 30.27M | 26.70M | 23.61M | 19.23M | 7.24M | 16.19M | 16.98M | 10.35M | 7.45M | 6.80M | 3.24M | 2.77M | 2.31M | 2.68M | 3.83M | 3.91M | 5.14M | 863.07K | 1.79M | 75.31K | 43.79K |
| Selling & Marketing | -2.05M | 0.00 | 0.00 | 0.00 | 2.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 372.24K | 1.12M | 2.17M | 1.00M | 0.00 | 0.00 | 0.00 |
| SG&A | 28.22M | 26.70M | 23.61M | 19.23M | 9.30M | 16.19M | 16.98M | 10.35M | 7.45M | 6.80M | 3.24M | 2.77M | 2.31M | 2.68M | 4.20M | 5.03M | 7.31M | 1.86M | 1.79M | 75.31K | 43.79K |
| Other Expenses | 0.00 | -14.42M | -20.97M | -19.31M | 0.00 | -19.88M | -3.86M | -1.95M | -3.14M | -682.90K | -682.90K | 18.95K | 339.19K | -10.32M | 3.48M | 2.97M | 2.70M | 2.37M | 119.60K | 0.00 | -1.82K |
| Operating Expenses | 87.69M | 64.28M | 88.00M | 53.19M | 42.00M | 47.69M | 54.13M | 33.94M | 29.45M | 19.29M | 13.33M | 8.51M | 7.45M | 5.55M | 9.49M | 15.43M | 26.92M | 10.03M | 3.74M | 579.92K | 43.79K |
| Cost & Expenses | 89.74M | 64.28M | 88.00M | 53.19M | 43.40M | 47.69M | 54.13M | 33.94M | 29.45M | 19.29M | 13.33M | 8.51M | 7.45M | 5.55M | 9.49M | 15.43M | 29.43M | 10.62M | 4.16M | 749.37K | 45.61K |
| Interest Income | 10.40M | 1.51M | 178.95K | 4.00K | 4.34K | 3.66M | 4.38M | 10.00K | 30.00K | 0.00 | 14.85K | 17.37K | 10.99K | 26.90K | 12.78K | 430.95K | 1.54M | 1.72M | 1.04M | 404.81K | 1.82K |
| Interest Expense | 16.46M | 4.40M | 281.00K | 255.00K | 32.52K | 556.10K | 1.65M | 1.08M | 0.00 | 448.00K | 0.00 | 0.00 | 4.71K | 6.33K | 107.04K | 116.74K | 75.56K | 11.77K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 90.74M | 2.51M | 2.46M | 2.00M | 1.39M | 1.49M | 348.21K | 72.50K | 68.36K | 49.72K | 42.89K | 146.89K | 295.22K | 710.54K | 3.78M | 2.74M | 3.28M | 737.53K | 240.99K | 9.41K | 1.82K |
| EBITDA | 1.00M | -52.63M | -62.74M | -37.13M | -16.80M | 11.66M | -32.19M | -30.98M | -20.30M | -12.20M | -11.02M | -5.48M | -4.41M | -8.65M | -5.41M | -16.03M | -18.58M | -6.13M | -2.97M | -527.20K | -41.96K |
| EBITDA Ratio | 0.00% | -8,633.17% | -4,764.29% | -5,985.47% | -6,546.15% | 24.59% | -37.31% | -1,075.82% | 0.00% | -854.30% | -486.04% | -191.35% | -157.79% | -298.82% | -1,786.78% | -4,499.47% | -308.42% | -302.42% | -203.69% | -57.52% | -2,300.00% |
| Operating Income | -89.74M | -72.09M | -86.19M | -53.19M | -42.76M | 12.38M | -18.25M | -31.07M | -28.73M | -19.15M | -11.07M | -7.23M | -4.71M | -9.38M | -9.20M | -19.20M | -23.40M | -8.60M | -3.21M | -536.61K | -43.79K |
| Operating Income Ratio | 0.00% | -10,235.63% | -4,764.29% | -6,185.23% | -6,766.39% | 21.95% | -50.73% | -1,078.69% | 0.00% | -844.40% | -487.93% | -252.32% | -170.09% | -777.06% | -3,047.63% | -7,198.94% | -388.45% | -423.79% | -338.91% | -252.21% | -2,400.00% |
| Total Other Income/Expenses | -526.14M | -19.15M | -24.87M | -14.01M | -1.04M | -3.30M | 1.91M | -854.00K | 5.54M | -427.00K | 14.85K | 17.37K | 6.28K | 20.57K | -94.26K | 314.20K | 1.47M | 1.71M | 1.04M | 404.81K | 1.82K |
| Income Before Tax | -615.87M | -78.78M | -88.60M | -52.91M | -28.41M | 6.60M | -15.42M | -32.13M | -28.69M | -19.07M | -11.05M | -7.21M | -4.71M | -9.36M | -9.30M | -18.88M | -21.94M | -6.88M | -2.17M | -131.80K | -41.96K |
| Income Before Tax Ratio | 0.00% | -11,185.94% | -4,897.84% | -6,152.33% | -4,494.86% | 11.70% | -42.85% | -1,115.76% | 0.00% | -841.02% | -487.27% | -251.71% | -169.86% | -775.36% | -3,078.84% | -7,081.10% | -364.13% | -339.36% | -229.12% | -61.95% | -2,300.00% |
| Income Tax Expense | -946.00K | -4.40M | -2.46M | -213.00K | -4.52M | -3.27M | -5.32M | -5.42M | -4.36M | -1.95M | -1.00M | -538.61K | -477.37K | -1.94M | -594.31K | -2.52M | -1.81M | -959.18K | -278.48K | -45.19K | -1.82K |
| Net Income | -614.93M | -74.38M | -86.15M | -52.70M | -23.88M | 9.87M | -10.09M | -26.71M | -24.34M | -17.12M | -10.05M | -6.67M | -4.23M | -7.42M | -8.66M | -32.29M | -20.13M | -5.92M | -1.89M | -86.61K | -41.96K |
| Net Income Ratio | 0.00% | -10,561.06% | -4,762.13% | -6,127.56% | -3,779.08% | 17.50% | -28.05% | -927.56% | 0.00% | -754.85% | -443.13% | -232.91% | -152.63% | -614.68% | -2,867.20% | -12,109.76% | -334.06% | -292.07% | -199.74% | -40.71% | -2,300.00% |
| EPS | -0.99 | -0.38 | -0.93 | -0.76 | -0.15 | 0.11 | -0.16 | -0.43 | -0.41 | -0.43 | -2.08 | -0.42 | -0.02 | -0.04 | -0.13 | -0.60 | -0.42 | -0.16 | -0.06 | 0.00 | 0.00 |
| EPS Diluted | -0.99 | -0.38 | -0.93 | -0.76 | -0.15 | 0.11 | -0.15 | -0.43 | -0.41 | -0.43 | -2.08 | -0.42 | -0.02 | -0.04 | -0.13 | -0.60 | -0.42 | -0.16 | -0.06 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 619.65M | 193.34M | 92.24M | 69.52M | 164.15M | 86.14M | 65.03M | 61.55M | 59.10M | 39.60M | 4.83M | 15.81M | 177.88M | 166.29M | 67.01M | 53.39M | 47.90M | 36.42M | 31.31M | 23.47M | 19.02M |
| Weighted Avg Shares Out (Dil) | 619.65M | 193.34M | 92.24M | 69.52M | 164.15M | 86.14M | 65.43M | 61.55M | 59.10M | 39.60M | 4.83M | 15.81M | 177.88M | 166.29M | 67.01M | 53.39M | 47.90M | 36.42M | 31.31M | 23.47M | 19.02M |
Summit Stock Skyrockets Nearly 700% YTD: Time to Sell or Hold?
The rally in SMMT stock is driven by encouraging updates on its oncology candidate, which has the potential to become the next standard of care in the NSCLC space.
Billionaire Israel Englander Just Quietly Took a Stake in This Potentially Lucrative Pharmaceutical Stock. Should You?
Millennium Management just initiated a position in a small biotech company developing a new cancer drug.
Up 700% This Year, Is It Too Late to Invest in This Stock?
The shares have experienced a pullback in the past couple of weeks.
Better Biotech Stock to Buy With $1,500 Right Now: Viking Therapeutics vs. Summit Therapeutics
It's hard to go wrong with either company, but one is more appealing.
3 Things You Need to Know If You Buy Summit Therapeutics Stock Today
It's easier to invest confidently when you know both the pros and the cons in full.
2 Soaring Stocks That Could Climb Another 112% and 120%, According to Wall Street Analysts
The investment bank analysts who follow these stocks think they can soar even further, with some caveats.
Is Summit Therapeutics a Millionaire Maker?
This company's promising cancer drug could challenge Merck's $25 billion crown jewel.
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 249,550 shares of common stock. Awards were made to ten new...
Summit Therapeutics Stock Jumps as Lung Cancer Drug Placed on FDA Fast Track
Summit Therapeutics (SMMT) shares surged Friday morning, a day after after the biopharmaceutical company said its developmental lung cancer drug was granted Fast Track designation by the Food and Drug Administration (FDA).
Could Summit Therapeutics Become the Next Merck?
Recent developments are forcing comparisons between these two drugmakers.
Source: https://incomestatements.info
Category: Stock Reports